Search

Your search keyword '"Matt Wasserman"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Matt Wasserman" Remove constraint Author: "Matt Wasserman" Topic business Remove constraint Topic: business
35 results on '"Matt Wasserman"'

Search Results

1. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

2. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India

Catalog

Books, media, physical & digital resources

3. Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium

4. Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

5. Letter to the editor regarding 'Budget impact analysis of pneumococcal conjugate vaccines in Colombia'

6. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis

7. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

8. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea

9. Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis

10. Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

11. Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges

12. Community-acquired pneumonia in infants: Not simply an acute event with complete recovery

13. A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019)

14. Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia

15. Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data

16. Response to McGirr et al.'s Comment on 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada'

17. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada

18. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico

19. 1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance

20. 1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age

21. 1510. Infant Pneumonia and Subsequent Risk of Chronic Respiratory Disorders

22. Trends in vaccine investment in middle income countries

23. Estimating the 10-year impact and current gap in pneumococcal conjugate vaccine (PCV) coverage in Asia

24. 1394. Impact of 7-Valent and 13-Valent Pneumococcal Conjugate Vaccines in the United States: A Systematic Literature Review

25. Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria

26. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK

27. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China

28. Understanding the economic impact of intravascular ultrasound (IVUS)

29. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine

30. Estimating the Vaccine Effectiveness Against Serotype 3 for the 13-Valent Pneumococcal Conjugate Vaccine: A Dynamic Modeling Approach

31. 1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination

34. Cost-Effectiveness of A Left Atrial Appendage Closure Device In Patients With Non-Valvular Atrial Fibrillation Unable or Unwilling to Tolerate Oral Anticoagulant Therapy In Italy And Spain

35. Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico